Initial data from the long-term study on CombiGene’s candidate drug for treating epilepsy indicate positive effects in the form of fewer seizures.

Initial data from CombiGene’s preclinical proof-of-concept-study (the long-term study) show that CombiGene’s candidate drug, CG01, has antiepileptic effects. The study has demonstrated that CG01 reduces the frequency of epileptic seizures in animals. It is expected that final data from the study will be presented during the first quarter of 2018.

Read more >>